Next Article in Journal
Association of Homozygous PROP1 Mutation in a Saudi Family with Combined Pituitary Hormone Deficiency
Previous Article in Journal
Patients with Diabetes Experienced More Serious and Protracted Sickness from the COVID-19 Infection: A Prospective Study
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Oral Health and Oral Health-Related Quality of Life in Patients with Primary Sjögren’s Syndrome

1
Department of Dentistry, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, 34000 Kragujevac, Serbia
2
Department of Medical Statistics and Informatics, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, 34000 Kragujevac, Serbia
3
Department of Radiology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, 34000 Kragujevac, Serbia
4
Department of Physiology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, 34000 Kragujevac, Serbia
5
Department of Histology and Embryology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, 34000 Kragujevac, Serbia
6
Department of Pharmacology and Toxicology, Faculty of Medical Sciences, University of Kragujevac, Svetozara Markovića 69, 34000 Kragujevac, Serbia
*
Authors to whom correspondence should be addressed.
Medicina 2023, 59(3), 473; https://doi.org/10.3390/medicina59030473
Submission received: 3 February 2023 / Revised: 20 February 2023 / Accepted: 24 February 2023 / Published: 27 February 2023
(This article belongs to the Section Dentistry and Oral Health)

Abstract

:
Background and Objectives: Oral disorders, frequently observed in patients with primary Sjögren’s syndrome, can profoundly affect patients’ daily lives and well-being, as oral health represents a fundamental part of general health. Saliva plays an essential part in maintaining and protecting oral health, so the decrease in its quantity and quality leads to chronic oral discomfort alongside a broad spectrum of problems. The objective of the present study was to evaluate the oral health of patients with primary Sjögren’s syndrome and establish its effect on the different domains of their oral health-related quality of life (OHRQoL). Materials and Methods: The research was designed as an observational case–control study with prospective data collection. Eighty patients, divided into two groups based on their oral status, participated in the study. All subjects underwent a complete oral examination. The OHRQoL was assessed using the Oral Health Impact Profile-14 (OHIP-14). Results: The most prevalent oral manifestation was exfoliative cheilitis, while 30% of subjects complained of chewing and swallowing difficulties. The OHIP-14 summary score was significantly higher in the patients with oral lesions (26.0 (5.0) vs. 17.0 (4.0), respectively; p < 0.001). Oral manifestations, systemic involvement, medication, and periodontal indexes were significantly associated with OHIP-14 scores. Conclusions: Patients with oral alterations had a substantially decreased OHRQoL. These findings emphasize the importance of oral diseases for patients’ well-being. Therefore, it is essential for dentists to be included in the multidisciplinary teams managing primary Sjögren’s syndrome, as improving patients’ oral status would lead to better oral health and enhanced OHRQoL.

1. Introduction

Primary Sjögren syndrome (pSS) is a chronic autoimmune rheumatic disease characterized by progressive focal lymphocytic infiltration of the exocrine glands, with an estimated prevalence of 0.05–1% in the European population [1]. In particular, salivary and lacrimal glands are the most affected, making xerostomia (dry mouth) and xerophthalmia (dry eyes) the main hallmarks of the pSS [2,3]. Up to 50% of patients might develop systemic complications such as arthritis, vasculitis, peripheral neuropathy, interstitial lung disease, and interstitial nephritis [4]. Severe fatigue, muscle/joint pain, and psychological distress are also often reported [5].
Saliva plays an essential part in maintaining and protecting oral health, so the decrease in its quantity and quality leads to chronic oral discomfort alongside a broad spectrum of problems [6]. Some of the most common oral manifestations associated with pSS are dental caries, atrophy of the oral mucosa, glossitis, oral ulcers, and fungal infections [7,8,9]. Due to hyposalivation, patients frequently experience chewing, swallowing, and speaking difficulties [8]. Additional issues include chemosensory dysfunction, halitosis, and trouble wearing dentures [8,9].
Oral disorders can profoundly affect patients’ daily lives and well-being, as oral health represents a fundamental part of general health. Therefore, serious efforts have been made in the past two decades to develop specific instruments for the evaluation of oral diseases’ impact on various aspects of the oral health-related quality of life (OHRQoL) [5]. Previous studies have demonstrated that xerostomia results in the deterioration of OHRQoL, so it can be hypothesized that patients suffering from pSS will also report physical, psychological, and social consequences due to oral problems [10,11].
The aim of this article was to evaluate the oral health of pSS patients and establish its effect on the different domains of their OHRQoL.

2. Materials and Methods

2.1. Study Design and Participants Selection

The research was designed as an observational case–control study with prospective data collection and performed at the Rheumatology Clinic of the University Clinical Centre of Kragujevac and the Dentistry Department of the Faculty of Medical Sciences, University of Kragujevac. The study protocol was approved by the Ethics Committee of the University Clinical Centre of Kragujevac (decision number 01/20-657), and it was conducted in accordance with the Helsinki Declaration of 1964 and its later amendments. The period of recruitment was between July 2021 and September 2022. The study included 80 patients (age over 18) with the diagnosis of pSS, according to the American College of Rheumatology/European League Against Rheumatism (ACR-EULAR) classification criteria [12]. These criteria include ocular symptoms (minimum one: dryness of the eyes persisting for more than 3 months, recurrent sandy-gritty eye irritation, or the need to use artificial tears for more than 3 months), oral symptoms (minimum one: dryness of the mouth persisting for more than 3 months, recurrent swelling of the salivary glands, or the need to sip fluid with swallowing), ocular signs (positive Schirmer’s test or Rose–Bengal score of ≥4), oral signs (positive result in one of the following tests: salivary scintigraphy, parotid sialography, or unstimulated salivary flow), focus score ≥ 1 in a minor salivary gland biopsy, and positive autoantibodies against SS-A and/or SS-B [13]. Patients were diagnosed with pSS if 4 out of 6 criteria were fulfilled; positive salivary gland biopsy or the presence of anti-Ro/SSA and anti-La/SSB autoantibodies are required for the diagnosis. The subjects under the age of 18, patients with systemic connective tissue diseases, mental disorders, malignant neoplasms, pregnant women, and active smokers were excluded from the study. Patients who met the inclusion criteria were invited to participate in the research. All subjects signed the written informed consent before enrollment. Participants were assigned into two groups based on their oral status. One group (case) consisted of subjects with oral lesions and symptoms, while the other group (control) comprised patients who did not experience any oral manifestations and symptoms besides the subjective feeling of dryness. Participants’ socio-demographic data and pSS clinical characteristics were recorded with a specially designed questionnaire for research purposes.

2.2. Sample Size

The sample size was calculated using G*Power software (v3.1.9.7; Faculty of Mathematics and Natural Sciences, Dusseldorf, Germany) based on the data on mean values of OHIP-14 in pSS patients from a recent study by Fernández Castro et al. [14]. In order to detect a difference in proportions of at least 30% between the two groups at a statistical significance level of 0.05 and power of 80%, a sample size of 40 subjects in each group was needed to meet the study requirements.

2.3. Oral Examination

The complete oral examination took place at the Dentistry Department of the Faculty of Medical Sciences. All patients were examined by the same doctor of dental medicine due to the objectivity and consistency of the gathered data. The investigator used a graduated periodontal probe and a standard dental mirror for each examination. Diagnosis of the oral manifestations was established according to WHO guidelines [6]. Lesion type, localization, clinical appearance, signs, and symptoms were documented. Additionally, the following periodontal parameters were collected and recorded: Community Periodontal Index of Treatment Need (CPITN), plaque index (PI), gingival index (GI), and sulcus bleeding index (SBI).

2.4. Assessment of the Oral Health-Related Quality of Life

OHRQoL was evaluated using the short Serbian version of the Oral Health Impact Profile (OHIP-14) questionnaire [15]. OHIP-14 represents one of the most widely applied tools worldwide for OHRQoL assessment in routine practice and clinical research [7]. It is a self-administered instrument that consists of 14 items divided into 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap [7]. Questions are scored on a 5-point Likert scale, with response options spanning from 0 to 4 (0—never, 1—hardly ever, 2—occasionally, 3—fairly often, and 4—very often). The single summary score may range between 0 and 56, with higher results implicating poorer OHRQoL [7].

2.5. Statistical Analysis

Statistical analysis was performed in the SPSS statistical program, version 22 for Windows (IBM SPSS Statistics 22, Armonk, NY, USA). A descriptive method was used for statistical data processing. Categorical variables were expressed as numbers and percentages, while continuous variables were shown as the median and interquartile range (IQR). The data do not follow a normal distribution, as determined by the Kolmogorov–Smirnov test. Fisher’s exact test was implemented for comparing categorical variables. Univariate analysis was used to investigate the relationship between different clinical characteristics and OHIP-14. The Mann–Whitney U test and the Kruskal–Wallis test were conducted to compare two or more independent samples, respectively. Person’s correlation and Spearman’s rank correlation tests assessed the degree of association between parameters of interest. Multiple linear regression analysis was performed to estimate the effects of statistically significant variables on the OHIP-14 score, the dependent variable. The level of significance for all statistical tests was set to 0.05.

3. Results

3.1. Participants’ Characteristics

A total of 80 pSS patients with a median age of 65.5 (26–81) years were included in the research. The majority of the study subjects were women (96.2%). Groups were similar in terms of age, education level, employment, marital status, alcohol intake, and physical activity (p > 0.05). The median disease duration was 8.0 (1–30) years (there was a statistically significant difference between the groups, p < 0.05). Socio-demographic and clinical pSS data are illustrated in Table 1 and Table 2, respectively.

3.2. Oral Findings

Table 3 shows the types of oral lesions and symptoms present in the case group. The most prevalent oral manifestation was exfoliative cheilitis (36.3%), followed by periodontal disease (30%), dental caries (20%), aphthae (16.3%), and atrophic glossitis (12.5%). About 32.5% of patients reported a burning sensation in the mouth, especially the tongue, and 30% complained of chewing and swallowing difficulties. A statistically significant difference between the groups was observed regarding all periodontal indexes measured (p < 0.001), as seen in Table 4.

3.3. Oral Health-Related Quality of Life

The OHIP-14 summary result was significantly higher in the case group than in the control group (26.0 (5.0) vs. 17.0 (4.0), respectively; p < 0.001), indicating that pSS patients with oral manifestations experienced greater impairment of the OHRQoL (Figure 1). A statistically significant difference was detected in all seven OHIP-14 subscales between the pSS patients with and without oral lesions (p < 0.001). Physical pain and psychological discomfort were domains with the highest median scores in both case and control groups (6.0 (1.0) and 6.0 (1.0) vs. 5.0 (1.0) and 4.0 (1.0), respectively). Outcomes for each dimension are depicted in Table 5 and Figure 2.

3.4. Factors Associated with OHRQoL

Patients with extraglandular symptoms tended to obtain significantly higher mean OHIP-14 results than those who did not have systemic involvement (24.0 (9.0) vs. 17.0 (3.0), respectively). This was also the case for the participants who received antimalarials and corticosteroids combined compared to chloroquine and hydroxychloroquine alone (25.0 (12.0) vs. 25.0 (9.0) vs. 17.0 (4.0), respectively). Table 6 shows the effects of different oral manifestations on the OHRQoL. The correlation between the periodontal parameters and the OHIP-14 score is shown in Table 7.
Multiple linear regression analysis was performed to assess the independent contribution of oral manifestations to the OHRQoL. Along with group allocation, all the cofactors that significantly correlated with OHIP-14 in the univariate analysis, such as systemic involvement, medication, and periodontal indexes, were put in the regression model. Due to collinearity between periodontal parameters, only CPITN was used, seeing that it provides the most comprehensive data on a patient’s periodontal status and treatment needs. Multiple linear regression analysis resulted in the model that explained 72.2% of the total variance (F = 47.783; p < 0.001) (Table 8).

4. Discussion

The main objective of our study was to evaluate the oral health status of pSS patients and determine its effect on different domains of OHRQoL. To date, there is limited information regarding this topic, so we aimed to reduce that knowledge gap by conducting the present research. Our results demonstrated that OHRQoL was substantially decreased in pSS subjects with oral lesions (for approximately 65% compared to participants without them), emphasizing their influence on all aspects of patients’ daily lives. Additionally, we found that oral manifestations were significantly and independently associated with OHIP-14 scores.
Oral health is an integrative part of general health and, thus, may profoundly impact the individual’s physical, psychological, and social functioning. OHRQoL represents a multidimensional concept created to measure how oral diseases affect patients’ well-being [16].
Saliva has a fundamental role in preserving oral homeostasis as it fulfills various important functions, including lubrication, pH buffering, antimicrobial activity, taste perception, and wound healing [17]. The prolonged decline in saliva quantity and quality during pSS may lead to the development of numerous lesions and symptoms in the oral cavity [6]. Some of the most frequent ones are candidiasis, traumatic lesions, aphthae, swallowing difficulties, and taste alteration, as reported by a recent systematic review [6]. Different research showed that patients with pSS had more commonly dysgeusia, burning sensation in the mouth, and halitosis compared to the controls, alongside impaired chemosensory and salivary functions [18]. Similarly, a comparative cross-sectional study comprising 58 pSS participants and 55 age- and gender-matched healthy controls demonstrated that the majority of pSS patients experienced chemosensory dysfunction, ageusia for basic tastes, halitosis, and burning sensations in the tongue [8]. Another research observed that pSS subjects had a high occurrence of lip dryness, exfoliative cheilitis, angular cheilitis, and small aphthae [19]. The findings of one cross-sectional study indicated that pSS patients often complained of swallowing and speaking difficulties, frequent fungal infections, and recurrently swollen salivary glands [10]. Our results revealed that our participants had similar signs and symptoms to those aforementioned. Exfoliative cheilitis was the most prevalent oral manifestation, followed by periodontal disease, dental caries, aphthae, and atrophic glossitis, while patients most commonly reported burning sensations in the tongue, as well as chewing and speaking problems. Regarding periodontal indexes, we observed significantly higher values in the patients presenting with oral manifestations. On the contrary, a study performed in southern China detected no difference between subjects with pSS and healthy controls, which might suggest better oral hygiene behavior of their pSS patients or more regular dental visits [20].
The OHIP-14 questionnaire, developed by Slade and Spencer in 1997, was used to assess the influence of oral alterations on patients’ well-being [21]. It is one of the most widely applied instruments for measuring the contribution of oral health to various aspects of people’s quality of life, such as physical, psychological, and social domains [22]. Our results showed that pSS subjects with oral lesions obtained significantly higher scores on the OHIP-14 index, indicating that their OHRQoL is worse by approximately 65% compared to patients without them. This discovery has important clinical implications as improving oral health status would possibly lead to remarkable OHRQoL enhancement and, consequently, greater life satisfaction. Other authors came to similar conclusions. One cross-sectional study demonstrated that oral distress is substantially increased in pSS, and that xerostomia-related symptoms pose a great burden to patients [10]. Another research study also reported a poor OHRQoL in 39 pSS subjects [5]. In a multicentric descriptive study, participants with pathological oral signs recorded significantly higher OHIP-14 results than those without them, which is in line with our findings [14]. Research conducted in Japan monitored changes in OHRQoL of pSS patients over a three-year period. It revealed a significant increase in their OHIP-14 scores compared to the initial assessment, especially in relation to the physical pain and psychological discomfort subscales [7]. Similarly, the findings of a recent study showed that OHRQoL in pSS seemed to be frequently impaired, with physical pain and psychological discomfort being the most affected OHIP-14 dimensions, which coincided with our results [23].
We analyzed variations in OHIP-14 scores based on the different characteristics of the study participants. Our results revealed that oral manifestations, extraglandular involvement, medication, and periodontal indexes were significantly associated with OHIP-14, which no other study has reported so far. Oral lesions are most likely the essential factor contributing to decreased OHRQoL in pSS patients. We demonstrated that patients who developed systemic complications during the course of the disease tended to have poorer OHRQoL. Our findings differ from the results of the only research that explored this relationship in which no correlation was found between extraglandular manifestations and OHIP-14 [14]. The type of medication used also affected participants’ OHRQoL. Our data indicated that subjects on hydroxychloroquine therapy recorded better OHIP-14 results in contrast to patients who were prescribed chloroquine or the combination of antimalarials and corticosteroids. To the best of our knowledge, no studies have investigated this topic up to now, so we consider this result a particular novelty of the present research. Our results also disclosed a significant association between periodontal indexes and OHIP-14 scores. They are important indicators of periodontal disease, which eventually leads to gingival recessions, tooth migration, and substantial tooth loss, all responsible for detrimental effects on all aspects of patients’ lives [20,24,25].
The main limitation of the present study is the small sample size due to a relatively low incidence of pSS in the general population and the ongoing COVID-19 pandemic making patients’ enrollment complicated. Further, the participants were recruited from only one rheumatology clinic registry, as it is the sole specialist unit for patients with connective tissue disorders in Kragujevac. Another limitation worth mentioning is that we used an OHRQoL measure of generic nature, which might not address all oral problems that pSS patients face daily. However, our plan is to conduct longitudinal research that would encompass a greater number of subjects with different clinical characteristics and whose quality of life would be evaluated by the disease-specific questionnaire, such as the PSS-QoL, which was recently validated in the Serbian language [26,27].

5. Conclusions

Participants with pSS accompanied by oral manifestations show significantly more reduced OHRQoL, especially concerning physical pain and psychological discomfort, compared with those who do not experience the same problems within the oral cavity. These findings emphasize the importance of oral diseases for patients’ well-being and have significant implications for routine clinical practice. Therefore, it is essential for dentists to be included in the multidisciplinary teams treating pSS, considering their pivotal position in identifying initial pSS signs early and referring a patient to a complete rheumatological assessment. Furthermore, regular dental appointments should be incorporated as a central part of the pSS management plan as they are required for timely diagnosis and successful treatment of different oral lesions and symptoms. That would improve not only the patients’ oral health, but also their OHRQoL. Future research in this area should explore the impact of different oral manifestations on the OHRQoL and investigate the efficacy of novel treatment options for oral lesions in pSS patients.

Author Contributions

Conceptualization, S.V. and D.M.; methodology, S.V. and M.S.; formal analysis, S.M. and R.V.; investigation, S.V. and J.D.; data curation, S.M.; writing—original draft preparation, S.V.; writing—review and editing, J.D. and D.S.; supervision, G.R. and D.M.; project administration, N.J.; funding acquisition, G.R. and D.M. All authors have read and agreed to the published version of the manuscript.

Funding

This work is supported by Internal Project N0 01/21 of Faculty of Medical Sciences, University of Kragujevac, Serbia (funding number 01-4209; 13.04.2021). The funds will provide support in terms of the article processing charge.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Ethics Committee of University Clinical Centre of Kragujevac (protocol code 01/20-657; 08.09.2020).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The data presented in this study (including the Serbian and English versions of the OHIP-14 questionnaire) are available on request from the corresponding authors.

Conflicts of Interest

The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.

References

  1. Bowman, S.J. Primary Sjögren’s syndrome. Lupus 2018, 27, 32–35. [Google Scholar] [CrossRef]
  2. Rizzo, C.; La Barbera, L.; Lo Pizzo, M.; Ciccia, F.; Sireci, G.; Guggino, G. Invariant NKT Cells and Rheumatic Disease: Focus on Primary Sjogren Syndrome. Int. J. Mol. Sci. 2019, 20, 5435. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  3. Mariette, X.; Criswell, L.A. Primary Sjögren’s Syndrome. N. Engl. J. Med. 2018, 378, 931–939. [Google Scholar] [CrossRef] [PubMed]
  4. Retamozo, S.; Acar-Denizli, N.; Rasmussen, A.; Horváth, I.F.; Baldini, C.; Priori, R.; Sandhya, P.; Hernandez-Molina, G.; Armagan, B.; Praprotnik, S.; et al. Systemic manifestations of primary Sjögren’s syndrome out of the ESSDAI classification: Prevalence and clinical relevance in a large international, multi-ethnic cohort of patients. Clin. Exp. Rheumatol. 2019, 118, 97–106. [Google Scholar]
  5. Stewart, C.M.; Berg, K.M.; Cha, S.; Reeves, W.H. Salivary dysfunction and quality of life in Sjögren syndrome: A critical oral-systemic connection. J. Am. Dent. Assoc. 2008, 139, 291–299. [Google Scholar] [CrossRef]
  6. Serrano, J.; Lopez-Pintor, R.M.; Gonzalez-Serrano, J.; Fernandez-Castro, M.; Casanas, E.; Hernandez, G. Oral lesions in Sjogren’s syndrome: A systematic review. Med. Oral Patol. Oral Cir. Bucal. 2018, 23, e391–e400. [Google Scholar] [CrossRef]
  7. Azuma, N.; Katada, Y.; Yoshikawa, T.; Yokoyama, Y.; Nishioka, A.; Sekiguchi, M.; Kitano, M.; Kitano, S.; Sano, H.; Matsui, K. Evaluation of changes in oral health-related quality of life over time in patients with Sjögren’s syndrome. Mod. Rheumatol. 2021, 31, 669–677. [Google Scholar] [CrossRef]
  8. Šijan Gobeljić, M.; Milić, V.; Pejnović, N.; Damjanov, N. Chemosensory dysfunction, Oral disorders and Oral health-related quality of life in patients with primary Sjögren’s syndrome: Comparative cross-sectional study. BMC Oral Health 2020, 20, 187. [Google Scholar] [CrossRef]
  9. Xin, W.; Leung, K.C.M.; Lo, E.C.M.; Mok, M.Y.; Leung, M.H. Sicca Symptoms, Oral Health Conditions, Salivary Flow and Oral Candida in Sjögren’s Syndrome Patients. Int. J. Environ. Res. Public Health 2020, 17, 3625. [Google Scholar] [CrossRef]
  10. Enger, T.B.; Palm, Ø.; Garen, T.; Sandvik, L.; Jensen, J.L. Oral distress in primary Sjögren’s syndrome: Implications for health-related quality of life. Eur. J. Oral Sci. 2011, 119, 474–480. [Google Scholar] [CrossRef]
  11. McMillan, A.S.; Leung, K.C.; Leung, W.K.; Wong, M.C.; Lau, C.S.; Mok, T.M. Impact of Sjögren’s syndrome on oral health-related quality of life in southern Chinese. J. Oral Rehabil. 2004, 31, 653–659. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  12. Shiboski, C.H.; Shiboski, S.C.; Seror, R.; Criswell, L.A.; Labetoulle, M.; Lietman, T.M.; Rasmussen, A.; Scofield, H.; Vitali, C.; Bowman, S.J.; et al. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren’s syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann. Rheum. Dis. 2017, 76, 9–16. [Google Scholar] [CrossRef] [PubMed]
  13. Jonsson, R.; Brokstad, K.A.; Jonsson, M.V.; Delaleu, N.; Skarstein, K. Current concepts on Sjögren’s syndrome—Classification criteria and biomarkers. Eur. J. Oral Sci. 2018, 126, 37–48. [Google Scholar] [CrossRef] [PubMed]
  14. Fernández Castro, M.; López-Pintor, R.M.; Serrano, J.; Ramírez, L.; Sanz, M.; Andreu, J.L.; Muñoz Fernández, S. Grupo EPOX-SSp. Protocolised odontological assessment of patients with primary Sjögren’s syndrome. Reumatol. Clin. 2021, 17, 25–31. [Google Scholar] [CrossRef]
  15. Lekić, M.; Daković, D.; Kovačević, V.; Čutović, T.; Ilić, I.; Ilić, M. Testing of the Serbian version of the Oral Health Impact Profile-14 (OHIP-14) questionnaire among professional members of the Serbian Armed Forces. Vojnosanit. Pregl. 2021, 78, 1257–1262. [Google Scholar] [CrossRef]
  16. Spanemberg, J.C.; Cardoso, J.A.; Slob, E.M.G.B.; López-López, J. Quality of life related to oral health and its impact in adults. J. Stomatol. Oral Maxillofac. Surg. 2019, 120, 234–239. [Google Scholar] [CrossRef]
  17. Uchida, H.; Ovitt, C.E. Novel impacts of saliva with regard to oral health. J. Prosthet. Dent. 2022, 127, 383–391. [Google Scholar] [CrossRef]
  18. Rusthen, S.; Young, A.; Herlofson, B.B.; Aqrawi, L.A.; Rykke, M.; Hove, L.H.; Palm, Ø.; Jensen, J.L.; Singh, P.B. Oral disorders, saliva secretion, and oral health-related quality of life in patients with primary Sjögren’s syndrome. Eur. J. Oral Sci. 2017, 125, 265–271. [Google Scholar] [CrossRef] [Green Version]
  19. Błochowiak, K.; Olewicz-Gawlik, A.; Polańska, A.; Nowak-Gabryel, M.; Kocięcki, J.; Witmanowski, H.; Sokalski, J. Oral mucosal manifestations in primary and secondary Sjögren syndrome and dry mouth syndrome. Postep. Dermatol. Alergol. 2016, 33, 23–27. [Google Scholar] [CrossRef] [Green Version]
  20. Leung, K.C.; McMillan, A.S.; Leung, W.K.; Wong, M.C.; Lau, C.S.; Mok, T.M. Oral health condition and saliva flow in southern Chinese with Sjögren’s syndrome. Int. Dent. J. 2004, 54, 159–165. [Google Scholar] [CrossRef]
  21. Slade, G.D. Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol. 1997, 25, 284–290. [Google Scholar] [CrossRef] [PubMed]
  22. Schmalz, G.; Patschan, S.; Patschan, D.; Ziebolz, D. Oral-Health-Related Quality of Life in Adult Patients with Rheumatic Diseases-A Systematic Review. J. Clin. Med. 2020, 9, 1172. [Google Scholar] [CrossRef] [Green Version]
  23. Rojas-Alcayaga, G.; Herrera, A.; Espinoza, I.; Rios-Erazo, M.; Aguilar, J.; Leiva, L.; Shakhtur, N.; Wurmann, P.; Geenen, R. Illness Experience and Quality of Life in Sjögren Syndrome Patients. Int. J. Environ. Res. Public Health 2022, 19, 10969. [Google Scholar] [CrossRef]
  24. Chuang, C.J.; Hsu, C.W.; Lu, M.C.; Koo, M. Increased risk of developing dental diseases in patients with primary Sjögren’s syndrome-A secondary cohort analysis of population-based claims data. PLoS ONE 2020, 15, e0239442. [Google Scholar] [CrossRef]
  25. Valenzuela-Narváez, R.V.; Valenzuela-Narváez, D.R.; Valenzuela-Narváez, D.A.O.; Córdova-Noel, M.E.; Mejía-Ruiz, C.L.; Salcedo-Rodríguez, M.N.; Gonzales-Aedo, O. Periodontal disease as a predictor of chronic kidney disease (CKD) stage in older adults. J. Int. Med. Res. 2021, 49, 3000605211033266. [Google Scholar] [CrossRef]
  26. Vujović, S.; Desnica, J.; Mijailović, S.; Milovanović, D. Translation, transcultural adaptation, and validation of the Serbian version of the PSS-QoL questionnaire—A pilot research. Vojn. Pregl. 2022, 80. [Google Scholar] [CrossRef]
  27. Lackner, A.; Stradner, M.H.; Hermann, J.; Unger, J.; Stamm, T.; Graninger, W.B.; Dejaco, C. Assessing health-related quality of life in primary Sjögren’s syndrome-The PSS-QoL. Semin. Arthritis Rheum. 2018, 48, 105–110. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Comparison of the median and range values of the OHIP-14 scores between the groups.
Figure 1. Comparison of the median and range values of the OHIP-14 scores between the groups.
Medicina 59 00473 g001
Figure 2. The median and range values of the OHIP-14 subscales’ scores (the dotted bars indicate subscales with the highest median values in both groups).
Figure 2. The median and range values of the OHIP-14 subscales’ scores (the dotted bars indicate subscales with the highest median values in both groups).
Medicina 59 00473 g002
Table 1. Socio-demographic characteristics of the patients.
Table 1. Socio-demographic characteristics of the patients.
VariablesCase Group
(N = 40)
Control Group
(N = 40)
Sex [n (%)]
Males
Females
2 (5.0)
38 (95.0)
1 (2.5)
39 (97.5)
Education [n (%)]
Elementary school
High school
University degree
Doctoral degree
9 (22.5)
18 (45.0)
11 (27.5)
2 (5.0)
9 (22.5)
20 (50.0)
10 (25.0)
1 (2.5)
Employment [n (%)]
Employed
Unemployed
Retired
4 (10.0)
12 (30.0)
24 (60.0)
3 (7.5)
15 (37.5)
22 (55.0)
Marital status [n (%)]
Single
In a relationship/married
Divorced
Widowed
1 (2.5)
29 (72.5)
3 (7.5)
7 (17.5)
3 (7.5)
26 (65.0)
2 (5.0)
9 (22.5)
Alcohol [n (%)]
Never
Sometimes
Regularly
36 (90.0)
4 (10.0)
0 (0.0)
39 (97.5)
1 (2.5)
0 (0.0)
Physical activity [n (%)]
Never
Sometimes
Regularly
30 (75.0)
8 (20.0)
2 (5.0)
29 (72.5)
7 (17.5)
4 (10.0)
Disease duration [median (IQR)]10 (13.0)7 (8.0)
IQR—interquartile range.
Table 2. pSS-related characteristics of the patients.
Table 2. pSS-related characteristics of the patients.
VariablesCase Group
(N = 40)
Control Group
(N = 40)
pSS systemic manifestations [n (%)]
Skin involvement6 (15.0)1 (2.5)
Musculoskeletal involvement37 (92.5)24 (60.0)
Renal involvement3 (7.5)2 (5.0)
Lung involvement4 (10.0)2 (5.0)
PNS involvement9 (22.5)3 (7.5)
Hematological involvement3 (7.5)3 (7.5)
Gastrointestinal involvement2 (5.0)0 (0.0)
Endocrine involvement3 (7.5)8 (20.0)
Immunological involvement7 (17.5)1 (2.5)
pSS serological findings [n (%)]
RF+29 (72.5)25 (62.5)
ANA+36 (90.0)31 (77.5)
pSS medication [n (%)]
Chloroquine29 (72.5)16 (40.0)
Hydroxychloroquine1 (2.5)18 (45.0)
Antimalarials + corticosteroids10 (25.0)6 (15.0)
pSS—Primary Sjögren Syndrome; PNS—peripheral nervous system; RF—rheumatoid factor; ANA—antinuclear antibodies.
Table 3. Frequency of oral lesions and symptoms in pSS patients.
Table 3. Frequency of oral lesions and symptoms in pSS patients.
Oral Lesions and SymptomsYes
n (%)
No
n (%)
Exfoliative cheilitis29 (36.3)51 (63.7)
Angular cheilitis6 (7.5)74 (92.5)
Aphthae13 (16.3)67 (83.7)
Traumatic lesions8 (10.0)72 (90.0)
Periodontal disease24 (30.0)56 (70.0)
Dental caries16 (20.0)64 (80.0)
Geographic tongue3 (3.8)77 (96.2)
Coated tongue8 (10.0)72 (90.0)
Atrophic glossitis10 (12.5)70 (87.5)
Denture stomatitis9 (11.3)71 (88.7)
Erythematous candidiasis3 (3.8)77 (96.2)
Lichen planus4 (5.0)76 (95.0)
Generalized stomatitis5 (6.3)75 (93.7)
Chewing difficulties24 (30.0)56 (70.0)
Swallowing difficulties24 (30.0)56 (70.0)
Speaking difficulties10 (12.5)70 (87.5)
Denture-wearing difficulties 15 (18.8)65 (81.2)
Burning sensation26 (32.5)54 (67.5)
Taste alteration20 (25.0)60 (75.0)
Table 4. Comparison of periodontal indexes between the groups.
Table 4. Comparison of periodontal indexes between the groups.
Periodontal Indexes aCase Group
Median (IQR)
Control Group
Median (IQR)
All Patients
Median (IQR)
CPITN *2.67 (0.67)1.50 (0.83)2.17 (1.30)
PI *1.96 (0.56)0.66 (0.38)1.29 (1.30)
GI *1.77 (0.59)0.83 (0.21)1.37 (0.96)
SBI *2.02 (0.74)0.41 (0.15)0.56 (1.64)
CPITN—Community Periodontal Index of Treatment Need; PI—plaque index; GI—gingival index; SBI—sulcus bleeding index; IQR—interquartile range; * p < 0.001; a Mann–Whitney U test.
Table 5. OHIP-14 domains’ scores.
Table 5. OHIP-14 domains’ scores.
OHIP-14 Domains aCase Group
Median (IQR)
Control Group
Median (IQR)
All Patients
Median (IQR)
Functional limitation *4.0 (1.0)2.0 (0.0)3.0 (2.0)
Physical pain *6.0 (1.0)5.0 (1.0)6.0 (1.0)
Psychological discomfort *6.0 (1.0)4.0 (0.0)5.0 (2.0)
Physical disability *2.0 (0.0)1.0 (1.0)1.0 (1.0)
Psychological disability *5.0 (2.0)3.0 (1.0)4.0 (2.0)
Social disability *3.0 (1.0)1.0 (1.0)2.0 (2.0)
Handicap *1.0 (1.0)1.0 (1.0)1.0 (0.0)
OHIP-14—Oral Health Impact Profile-14; IQR—interquartile range * p < 0.001; a Mann–Whitney U test.
Table 6. Oral manifestations and OHIP-14.
Table 6. Oral manifestations and OHIP-14.
Oral Manifestations aOHIP-14 Score
Median (IQR)
Exfoliative cheilitis **
Yes
No

26.0 (5.0)
18.0 (5.0)
Angular cheilitis *
Yes
No

26.0 (8.0)
20.0 (9.0)
Aphthae **
Yes
No

27.0 (4.0)
19.0 (8.0)
Traumatic lesions *
Yes
No

26.0 (6.0)
19.5 (9.0)
Periodontal disease **
Yes
No

26.0 (4.0)
18.0 (8.0)
Caries *
Yes
No

25.5 (3.0)
19.0 (9.0)
Coated tongue *
Yes
No

26.5 (5.0)
19.5 (9.0)
Atrophic glossitis **
Yes
No

30.0 (5.0)
19.0 (9.0)
Denture stomatitis *
Yes
No

27.0 (5.0)
19.0 (9.0)
Generalized stomatitis *
Yes
No

29.0 (12.0)
20.0 (9.0)
Chewing difficulties **
Yes
No

27.0 (5.0)
18.0 (8.0)
Swallowing difficulties **
Yes
No

26.5 (5.0)
18.0 (7.0)
Speaking difficulties *
Yes
No

28.0 (6.0)
19.0 (9.0)
Denture-wearing difficulties **
Yes
No

27.0 (6.0)
19.0 (9.0)
Burning sensation **
Yes
No

26.5 (5.0)
18.0 (7.0)
Taste alteration **
Yes
No

26.0 (5.0)
17.0 (4.0)
OHIP-14—Oral Health Impact Profile-14; IQR—interquartile range; * p < 0.05; ** p < 0.001; a Mann–Whitney U test.
Table 7. The correlation between the periodontal parameters and the OHIP-14.
Table 7. The correlation between the periodontal parameters and the OHIP-14.
Variable aCPITN *PI *GI *SBI *
OHIP-140.6000.7630.7200.681
OHIP-14—Oral Health Impact Profile-14; CPITN—Community Periodontal Index of Treatment Need; PI—plaque index; GI—gingival index; SBI—sulcus bleeding index; * p < 0.001; a Spearman’s rank correlation test.
Table 8. Multiple linear regression analysis of factors influencing the OHIP-14.
Table 8. Multiple linear regression analysis of factors influencing the OHIP-14.
Variables aBβ95% Confidence Interval
Group allocation *9.1120.7316.924–11.301
Systemic involvement1.2360.066−1.311–3.782
Medication0.0080.001−0.971–0.987
CPITN1.1950.144−0.176–2.566
OHIP-14—Oral Health Impact Profile-14; CPITN—Community Periodontal Index of Treatment Need; * p < 0.001; a Multiple linear regression analysis.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Vujovic, S.; Desnica, J.; Stevanovic, M.; Mijailovic, S.; Vojinovic, R.; Selakovic, D.; Jovicic, N.; Rosic, G.; Milovanovic, D. Oral Health and Oral Health-Related Quality of Life in Patients with Primary Sjögren’s Syndrome. Medicina 2023, 59, 473. https://doi.org/10.3390/medicina59030473

AMA Style

Vujovic S, Desnica J, Stevanovic M, Mijailovic S, Vojinovic R, Selakovic D, Jovicic N, Rosic G, Milovanovic D. Oral Health and Oral Health-Related Quality of Life in Patients with Primary Sjögren’s Syndrome. Medicina. 2023; 59(3):473. https://doi.org/10.3390/medicina59030473

Chicago/Turabian Style

Vujovic, Sanja, Jana Desnica, Momir Stevanovic, Sara Mijailovic, Radisa Vojinovic, Dragica Selakovic, Nemanja Jovicic, Gvozden Rosic, and Dragan Milovanovic. 2023. "Oral Health and Oral Health-Related Quality of Life in Patients with Primary Sjögren’s Syndrome" Medicina 59, no. 3: 473. https://doi.org/10.3390/medicina59030473

Article Metrics

Back to TopTop